Products
Moflerafusp Biosimilar Fusion Protein (SIRPα) for Research
Cat No.: GMP-Bios-INN-1286
Anti-SIRPA therapeutic antibody (Pre-made Moflerafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Moflerafusp is a fusion protein described in WHO INN lists. It is in early-stage development. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1286-1mg | 1mg | 3090 |
| GMP-Bios-INN-1286-10mg | 10mg | |
| GMP-Bios-INN-1286-100mg | 100mg | |
| GMP-Bios-INN-1286-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Moflerafusp biosimilar, Fusion Protein targeting SIRPA: Recombinant therapeutic protein targeting SIRP Alpha/CD172a/SIRPA/Tyrosine-protein phosphatase non-receptor type substrate 1 |
| INN Name | Moflerafusp |
| Target | SIRPA |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
